Literature DB >> 8995141

Definitive radiation management for carcinoma of the glottic larynx.

B D Moose1, K M Greven.   

Abstract

Radiation therapy offers excellent cure rates and preservation of the larynx in the majority of early-stage glottic cancers. Outcome may vary because of patient-, tumor-, and treatment-related variables. Carefully selected advanced lesions may also be successfully managed with irradiation. Hyperfractionation and combined chemotherapy-radiotherapy protocols seem to be promising strategies for the improvement of the therapeutic ratio in treatment of patients with more advanced lesions.

Entities:  

Mesh:

Year:  1997        PMID: 8995141

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  4 in total

1.  Detecting recurrent laryngeal carcinoma after radiotherapy: room for improvement.

Authors:  Jolijn Brouwer; Evelien J Bodar; Remco De Bree; Johannes A Langendijk; Jonas A Castelijns; Otto S Hoekstra; C René Leemans
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-11-19       Impact factor: 2.503

2.  Objective and self-evaluation voice analysis after transoral laser cordectomy and radiotherapy in T1a-T1b glottic cancer.

Authors:  Nicola Lombardo; Teodoro Aragona; Said Alsayyad; Girolamo Pelaia; Rosa Terracciano; Rocco Savino
Journal:  Lasers Med Sci       Date:  2017-10-26       Impact factor: 3.161

3.  Transoral laser surgery for recurrent glottic cancer after radiotherapy: oncologic and functional outcomes.

Authors:  F Del Bon; C Piazza; S Mangili; L O Redaelli De Zinis; P Nicolai; G Peretti
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-08       Impact factor: 2.124

4.  Salvage carbon dioxide transoral laser microsurgery for laryngeal cancer after (chemo)radiotherapy: a European Laryngological Society consensus statement.

Authors:  Cesare Piazza; Alberto Paderno; Elisabeth V Sjogren; Patrick J Bradley; Hans E Eckel; Antti Mäkitie; Nayla Matar; Vinidh Paleri; Giorgio Peretti; Roberto Puxeddu; Miquel Quer; Marc Remacle; Vincent Vander Poorten; Isabel Vilaseca; Ricard Simo
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-05       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.